August 29, 2020 FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
August 25, 2020 CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector
August 21, 2020 Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast – correction